Kun Yang, Xiaodong Liu, Wei Peng, Fang Hua, Lan Li, Kun Chen, Jin Zhang, Shan Luo, Wanting Li, Yuxi Ding, Jie Chen, Jian Xiao
Thalidomide is a therapeutic option for patients with β-thalassemia by increasing fetal hemoglobin and thereby reducing the requirement for blood transfusions. However, information on changes in erythropoiesis and iron homeostasis during thalidomide treatment is lacking. This study investigated the effects of thalidomide treatment on hematologic, erythropoietic, and ironstatus parameters in 22 patients with transfusion-dependent β-thalassemia (TDT). Thalidomide significantly improved anemia endpoints, including increases in hemoglobin ( p <0...
2024: Mediterranean Journal of Hematology and Infectious Diseases